This week, physicists at CERN reported the transmutation of lead into gold in the Large Hadron Collider, raising the ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

PD-1 functions as an immune checkpoint, negatively regulating T cell activation, and plays an important role in cancer’s evasion from a patient’s immune system, as the National Cancer Institute ...

In the Phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly outperformed tislelizumab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

Reasonably, authors should adapt the title and the abstract in a way that it recapitulates the whole data, which is HOXA1/RNUX2/PRDX2 axis control of cell death, including ferroptosis and apoptosis in ...

The University of Hong Kong, Hong Kong, Hong Kong. Search for other works by this author on: ...

Now visualized using cryo-electron microscopy, the carrier’s lock-like mechanism could be the key to tackling diseases like cancer, diabetes ... it needs to be transferred inside the cell’s ...

Signet cell cancer is a rare type of cancer that mostly starts in the glandular cells. It is also called signet ring cell cancer. Nearly 57 out of 100 (57%) of all signet cell cancers start in the ...